BlackBerry Gets Downgraded to Sell Along With Host of Other Stocks

Andrew Klips |

BlackBerry Gets Downgraded to Sell Along With Host of Other StocksEvery day is greeted with a series of changes in analysts opinions. Friday was no different with several big names getting cut to “sell” ratings, including:

BlackBerry (BBRY) was downgraded to a sell rating from neutral by MKM Partners. MKM citing concerns over the likelihood of success in the company’s new BlackBerry 10 phones and operating system. MKM believes that the odds of failure outweigh the chance of success with sales already stalling in the United Kingdom and a far smaller selection of popular applications.  Analysts lowered their price target from $12.00 to $10.00. Shares of BBRY are trading down 3 percent at $13.50 in early morning trading.

Agrium, Inc. (AGU) was downgraded by Dahlman Rose from a buy rating to a sell rating.  Dahlman Rose holds a price target of $88.00 for Agrium shares.  The reasons for the downgrade were more industry-wide as Dahlman believes the nitrogen, phosphorous and potassium markets are facing stiff headwinds for future growth.  Shares of AGU have fallen more than 6 percent in Friday morning trading to $100.

Dahlman wasn’t done with fertilizer play downgrades. Analysts also slashed CF Industries Holdings, Inc. (CF) from buy to sell on Friday with a price target of $170.00. That’s a 17 percent downside from Thursday’s closing price.  Shares have shed 1.6 percent to $200 this morning.

Newfield Exploration Co. (NFX) was downgraded by the computer-based metrics at TheStreet from a hold to a sell rating.  Reasons cited were weakness in multiple areas, including a high debt-to-equity ratio of 1:10, deteriorating net income in the latest quarter compared to the year prior quarter and “generally disappointing historical performance in the stock itself.” Despite the downgrade, shares are ahead by about 1 percent this morning after plummeting about 20 percent in the past five days.

C.R. Bard, Inc. (BCR) was downgraded by analysts at Goldman Sachs from neutral to a sell. Goldman’s 12-month price target for the stock was lowered from $99.00 to $95.00. The firm noted risks associated with clinical trials and an expanding P/E ratio while earnings estimates were lowered as rationale for the ratings cut. Shares of BCR are down by less than 1 percent at $98 in morning trading.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
BCR C.R. Bard Inc. 209.46 2.60 1.26 297,935
CF CF Industries Holdings Inc. 28.23 -0.49 -1.71 2,291,975
AGU Agrium Inc. 100.14 -0.63 -0.63 195,911
GDEN Golden Entertainment Inc. 12.25 0.03 0.25 7,414
NFX Newfield Exploration Company 46.19 0.08 0.17 1,400,952
BBRY BlackBerry Limited 7.51 -0.01 -0.13 2,530,133

Comments

Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Cloudera

Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…